Chinese switch hurts Bayer
This article was originally published in OTC Bulletin & The Rose Sheet
An “unexpected” move by the China Food and Drug Administration (CFDA) to reverse-switch two of its leading OTC products, in combination with “persistently weak business development in the US”, caused Bayer’s Consumer Health sales to fall by 2.9% to €5.86 billion in 2017, the German company reported.
You may also be interested in...
Bayer's Consumer Health chief Heiko Schipper hopes a focus on innovation and a leaner portfolio will help return business to mid-single-digit growth by 2022. German firm has identified North American business as the "key area to fix."